Pragmatech AI Solutions, S.L.

Based in Oviedo, Spain, Pragmatech AI Solutions, S. L. specializes in providing advanced artificial intelligence solutions designed to enhance decision-making processes within the healthcare sector. Founded in 2021 in Oviedo, Spain, Pragmatech AI Solutions, S.

L. focuses on developing AI technologies for healthcare applications. The company was established to address significant challenges in clinical microbiology and infectious diseases. It secured EUR 655,000 in venture funding on January 12, 2026, led by First Drop, which represents the total amount raised to date.

Pragmatech AI specializes in the development of advanced artificial intelligence solutions tailored primarily for the healthcare sector. The company offers a comprehensive suite of products designed to enhance clinical decision-making and optimize healthcare services. Their flagship offerings include Clinical Decision Support Systems (CDSS) that leverage machine learning and big data analytics to provide actionable insights based on data collected through Omic technologies. Pragmatech’s solutions aim to address critical challenges in clinical microbiology and infectious diseases, focusing on improving diagnosis, treatment, and patient care quality.

These products are utilized by healthcare providers, clinical laboratories, and pharmaceutical companies across various international markets, including Europe and North America, aiming to combat issues such as antibiotic resistance and enhance patient outcomes. Pragmatech AI generates revenue through a structured model that includes direct sales of its AI-driven software products and potential partnerships with healthcare institutions and research organizations. The company’s transaction framework encompasses subscription-based access to its Clinical Decision Support Systems, providing clients with ongoing support, updates, and enhancements. Additionally, Pragmatech engages in collaborations that involve customized solutions tailored to specific client needs, fostering long-term relationships in the healthcare ecosystem.

Pricing plans reflect the value provided by their proprietary technologies, including their trademarked product, iLynx®, which integrates advanced natural language processing tailored for the healthcare domain. This pricing model is designed to ensure that clients receive robust support and continuous improvements aligned with evolving healthcare demands. In January 2026, Pragmatech AI Solutions, S. L.

raised EUR 655,000 in venture funding led by new investor First Drop. The company plans to utilize these funds for the development of upcoming AI-driven products aimed at further enhancing clinical decision-making tools. Pragmatech is also exploring expansion into additional markets, specifically targeting further growth in North America and parts of Asia by the end of 2027, to increase its presence in the global healthcare technology landscape.